ZIVO Bioscience (ZIVOW) -92.0% to $0.04 06 Jan 2026 closed: liquidity outlook
The market closed with ZIVOW stock plunging 92.00% to $0.044 on NASDAQ in the United States on 06 Jan 2026. This collapse follows a previous close of $0.55 and occurred on unusually thin trading volume 3,000 shares. We flag liquidity stress and valuation gaps as primary drivers.
Trading in ZIVO Bioscience, Inc. (ZIVOW) is concentrated and volatile. With a market cap near $164,234 and just 3,732,589 shares outstanding, a handful of trades can move the price sharply. Below we break down technicals, fundamentals, the Meyka grade, and model forecasts to help investors assess risk and opportunity.
ZIVOW stock session summary
ZIVOW stock closed at $0.044 on NASDAQ in the United States. The one‑day change was -92.00%, a drop of -$0.506 from the prior close of $0.55.
Volume was 3,000 shares versus an average volume of 4,285. Market capitalization rounded is $164,234. The trade shows extreme downside in a low‑liquidity listing.
ZIVOW stock drivers and news
There was no major public earnings release tied to today’s move. The most recent earnings announcement date on file is 2022‑12‑30. Market participants point to forced selling and scarce float as likely causes.
For company context visit the ZIVO site ZIVO Bioscience website. We found no SEC filing or press event that directly explains the full 92.00% drop.
ZIVOW stock technicals and trading metrics
Technical indicators show weak momentum. RSI is 39.09 and MACD histogram is -0.02, indicating bearish pressure. Average price over 50 and 200 days is $0.95, far above the current price.
Thin liquidity is decisive. Average volume is 4,285 and today’s volume was 3,000, so single large orders can swing price. ATR is 0.21, highlighting outsized intraday movement relative to price.
ZIVOW stock fundamentals and valuation
Fundamentals show limited scale and negative earnings. Revenue per share is $0.05 and net income per share is -$2.22. Book value per share is $0.09 and cash per share is $0.01.
Valuation ratios are skewed by the collapse. Price to sales is 172.08 and trailing PE is negative. The current ratio is 0.08, signalling working capital stress for the small biotechnology issuer.
Meyka AI rates ZIVOW with a score out of 100 and forecast
Meyka AI rates ZIVOW with a score out of 100: 65.59 / 100, Grade B, Suggestion: HOLD. This grade factors S&P 500 and sector comparison, financial growth, key metrics, forecasts, analyst consensus, and industry context.
Meyka AI’s forecast model projects monthly $0.19, quarterly $1.46, and yearly $0.83. Compared to the current price of USD 0.044, the yearly model implies an upside of about 1,794.93%. Forecasts are model‑based projections and not guarantees.
ZIVOW stock trading outlook and strategy
We view ZIVOW stock as highly speculative. The combination of tiny market cap, low float, and weak liquidity raises execution and funding risk. Traders should expect large bid‑ask spreads and sudden price gaps.
For risk management consider position size limits and use limit orders. For research, compare sector peers in Biotechnology and monitor filings on NASDAQ and the company website. Meyka AI provides this as an AI‑powered market analysis platform insight, not investment advice.
Final Thoughts
ZIVOW stock closed sharply lower on 06 Jan 2026, falling 92.00% to $0.044 on NASDAQ in the United States. The move looks driven by liquidity limits rather than an easily identifiable earnings shock. Key fundamentals show low revenue per share $0.05, negative net income per share -$2.22, and a strained current ratio 0.08, all signaling balance‑sheet pressure. Meyka AI rates ZIVOW at 65.59 / 100 (Grade B, HOLD) and highlights model forecasts of $0.19 monthly and $0.83 yearly. Using the current price USD 0.044, the model implies about 1,794.93% upside, though that projection is highly model‑dependent. Investors who consider ZIVOW stock should prioritize liquidity checks, monitor company filings, and set tight risk limits. Small cap biotech listings like ZIVO Bioscience can produce large headline moves. Use limit orders and confirm any large price swings with filings or market notices before trading.
FAQs
The fall appears linked to extreme low liquidity and concentrated selling rather than a clear public earnings update. With only **3,000** shares traded, few orders can move the price. Check SEC filings and company notices for confirmation.
Meyka AI rates ZIVOW at **65.59 / 100**, Grade **B**, Suggestion: **HOLD**. The model flags liquidity risk and mixed fundamentals. Forecasts show wide upside scenarios but are not guarantees.
Meyka AI’s short targets show **monthly $0.19** and **quarterly $1.46**. Given the current **USD 0.044** price, those targets reflect model scenarios, not assured outcomes. Use strict risk controls.
Confirm filings and announcements on the company site and exchange pages. Start with the company website [ZIVO Bioscience website](https://www.zivobioscience.com) and the NASDAQ listing page for ZIVOW.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
